Interestingly as can be seen in the 4C looking at the 12 month cash use/burn
Cynata only spent a NET $4.02m the last 12 months.
This has placed the business in a very strong position to ride out the biotech downturn unlike many others caught out quickly.
If we take out the one off FUJI payment of $6.732m, we get a true look at burn for say next 12 months. of $10.75m. I had forecast for CY2022 around $12m ($1m pm), and the next 6 months should lift it there with US trial set up costs.
Of note, which is one thing I have really liked about Cynata. R&D % spend of cash. Again removing FUJI payment.
R&D for 12 months to end June was $8.93m Total Cash burn (adding back FUJI) $10.75m
leaving just a NET G&A burn of just $1.82m or $151k per month and an R&D spend of 83%!
CYP Price at posting:
40.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)